These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22188169)

  • 1. When to use biological agents in inflammatory bowel disease.
    Corte C; Saxena P; Tattersall S; Selinger C; Leong RW
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1141-9. PubMed ID: 22188169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R; Denis MA; Dewit O
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the management of inflammatory bowel disease in adults.
    Carter MJ; Lobo AJ; Travis SP;
    Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
    [No Abstract]   [Full Text] [Related]  

  • 5. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J; Göke B; Ochsenkühn T
    Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
    Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics for inflammatory bowel disease: a critical appraisal.
    Sans M
    Dig Dis; 2009; 27 Suppl 1():111-4. PubMed ID: 20203506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the dose of thioguanine the key to better safety profile?
    Chevaux JB; Peyrin-Biroulet L
    Dig Liver Dis; 2011 Feb; 43(2):96-7. PubMed ID: 21156354
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey.
    Sung JJ; Kamm MA; Marteau P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):183-93. PubMed ID: 19929931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
    Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
    Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.